1. Home
  2. QLGN vs KWE Comparison

QLGN vs KWE Comparison

Compare QLGN & KWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • KWE
  • Stock Information
  • Founded
  • QLGN 1996
  • KWE 2017
  • Country
  • QLGN United States
  • KWE Canada
  • Employees
  • QLGN N/A
  • KWE N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • KWE
  • Sector
  • QLGN Health Care
  • KWE
  • Exchange
  • QLGN Nasdaq
  • KWE Nasdaq
  • Market Cap
  • QLGN 2.8M
  • KWE 3.1M
  • IPO Year
  • QLGN N/A
  • KWE N/A
  • Fundamental
  • Price
  • QLGN $3.16
  • KWE $10.85
  • Analyst Decision
  • QLGN
  • KWE
  • Analyst Count
  • QLGN 0
  • KWE 0
  • Target Price
  • QLGN N/A
  • KWE N/A
  • AVG Volume (30 Days)
  • QLGN 10.7K
  • KWE 3.0M
  • Earning Date
  • QLGN 08-13-2025
  • KWE 08-15-2025
  • Dividend Yield
  • QLGN N/A
  • KWE N/A
  • EPS Growth
  • QLGN N/A
  • KWE N/A
  • EPS
  • QLGN N/A
  • KWE N/A
  • Revenue
  • QLGN N/A
  • KWE $2,115,849.00
  • Revenue This Year
  • QLGN N/A
  • KWE N/A
  • Revenue Next Year
  • QLGN N/A
  • KWE N/A
  • P/E Ratio
  • QLGN N/A
  • KWE N/A
  • Revenue Growth
  • QLGN N/A
  • KWE 121.88
  • 52 Week Low
  • QLGN $2.85
  • KWE $3.86
  • 52 Week High
  • QLGN $29.44
  • KWE $116.99
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 32.55
  • KWE 62.90
  • Support Level
  • QLGN $3.37
  • KWE $7.16
  • Resistance Level
  • QLGN $3.70
  • KWE $14.28
  • Average True Range (ATR)
  • QLGN 0.21
  • KWE 1.91
  • MACD
  • QLGN -0.05
  • KWE 0.27
  • Stochastic Oscillator
  • QLGN 0.00
  • KWE 53.26

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About KWE KWESST Micro Systems Inc.

KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.

Share on Social Networks: